KLP Kapitalforvaltning AS Acquires Shares of 4,300 Krystal Biotech, Inc. (NASDAQ:KRYS)

KLP Kapitalforvaltning AS acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,300 shares of the company's stock, valued at approximately $674,000.

A number of other hedge funds have also recently made changes to their positions in the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Krystal Biotech in the 3rd quarter worth about $40,000. Avanza Fonder AB bought a new stake in Krystal Biotech during the 4th quarter worth approximately $119,000. KBC Group NV raised its stake in shares of Krystal Biotech by 46.3% in the fourth quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after purchasing an additional 297 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Krystal Biotech by 74.4% in the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares in the last quarter. Finally, US Bancorp DE boosted its position in shares of Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after buying an additional 82 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

NASDAQ:KRYS traded down $6.83 during trading hours on Friday, reaching $171.30. The stock had a trading volume of 444,673 shares, compared to its average volume of 292,083. The stock has a market cap of $4.93 billion, a P/E ratio of 57.29 and a beta of 0.75. The stock has a 50 day simple moving average of $173.27 and a 200 day simple moving average of $173.00. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34.

Remove Ads

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period in the prior year, the firm earned $0.30 earnings per share. The company's revenue was up 116.4% compared to the same quarter last year. On average, equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KRYS has been the topic of several recent analyst reports. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective on the stock. Citigroup boosted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Chardan Capital increased their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. HC Wainwright restated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $220.00.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 14.10% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).